ÂÜÀòÂÒÂ×

Chuck Caldwell is an experienced researcher in medical oncology and immuno-oncology assays, currently serving as the Director of Translational Oncology at Pfizer. Caldwell has previously held various roles, including Associate Director at Seagen and Science Manager at Flagship Biosciences, where they managed teams focused on biomarker strategies for clinical trials. They earned a PhD in Bioengineering and Biomedical Engineering from the University of Missouri, where they also developed innovative peptide-based diagnostic applications during their doctoral studies. Caldwell is passionate about driving innovative cancer molecules to the market.